3.46  0.06 (1.76%)		03-27 16:00
Open: 3.41 High: 3.58 Volume: 36,708		Pre. Close: 3.4 Low: 3.37 Market Cap: 102(M)

Short term
Mid term
Targets	6-month :	4.32	1-year :	4.68
Resists	First :	3.7	Second :	4.01
Pivot price	3.5
Supports	First :	3.2	Second :	2.66
MAs	MA(5) :	3.4	MA(20) :	3.49
	MA(100) :	3.75	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	39.8	D(3) :	34.5
RSI	RSI(14): 46.1
52-week	High :	26.5	Low :	2.56

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TTRX ] has closed above bottom band by 39.9%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.58 - 3.61	3.61 - 3.63
Low:	3.32 - 3.35	3.35 - 3.37
Close:	3.43 - 3.47	3.47 - 3.5

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.

Tue, 24 Mar 2026
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat

Tue, 24 Mar 2026
Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com

Tue, 24 Mar 2026
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView

Tue, 24 Mar 2026
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Tue, 24 Mar 2026
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - Business Wire

Mon, 23 Mar 2026
Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	29 (M)
Held by Insiders	1.049e+007 (%)
Held by Institutions	64.3 (%)
Shares Short	70 (K)
Shares Short P.Month	0 (K)

EPS	-3.94e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-78.7 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	81600
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.